Dr. Clay B. Siegall, PhD. is a leading scientist and researcher with a focus on cancer research and the development of drug therapies. He first received a Bachelors of Science degree in Zoology from the University of Maryland and was later awarded his PhD. in Genetics from the George Washington University. In 1997, Dr. Siegall partnered in founding Seattle Genetics Inc. He served as the institution’s Executive Vice President and Chief Scientific Officer from 1997, President from 2000, and was later appointed its Chief Executive Officer in 2002.
Before venturing out to incept Seattle Genetics, Dr. Siegall amassed a wealth of experience of over 20 years in the cancer research field. He has worked for various prominent institutions such as the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, Ultragenyx Pharmaceutical Inc., Alder Biopharmaceutical Inc., and Mirna Therapeutics Inc. He currently serves as the Director of the Washington Biotechnology and Biomedical Association.
Dr. Siegall has also built up an impressive body of work, holding 15 patents and authoring more than 70 scientific and academic papers. He is also a prominent commentator on the current trends within the industry. He has most recently written about the new strategies top scientists around the world are adopting so as to improve the integrity of their research practice. Further, he has opined on the curious case of the baby with three genetic parents, and what this might mean for future genetics research.
As the CEO of Seattle Genetics, Dr. Clay Siegall places great emphasis on meticulous scientific research, innovative drug enhancing projects, and a commitment to assisting the patients. He has achieved many significant milestones in this leadership role, most noticeably leading the company to the top of the market by spearheading the development of anti-drug conjugates Further, he led the company’s effort to secure FDA approval for its inaugural ADC product, which was approved in 2011 and is bow distributed in over 65 countries.
Dr. Siegall has also led Seattle Genetics’ entry into numerous beneficial licenses for its ADC technological advancement. The company partnered with multinationals like Pfizer, GlaxoSmithKline, AbbVie, and Genentech. These licenses have generated in excess of 350 million dollars to date. He has also successfully headed the company’s capital generation activities, netting over $1.2 billion through various financing channels. This includes the company’s 2001 IPO.
The cancer research community has lauded Dr. Siegall for his skill and contributions through various industry awards.